Benjamin Levy, MD:So, this is a 72-year-old female with a 40-pack year history of smoking who presented to her primary care physician with progressive shortness of breath and increased cough. Given her smoking history, the primary care physician ordered a chest x-ray, which revealed a right upper lobe opacity. Based on those findings, the patient went on to get a CAT scan of the chest, abdomen, and pelvis that revealed a 3-cm right upper lobe mass, pleural thickening, as well as a left adrenal gland nodule. Based on the pattern of spread and to both stage and diagnose the patient, a core needle biopsy was performed on the left adrenal mass, which came back as a squamous cell carcinoma that was p40-positive and p63-positive.
Based on the fact that this occurred in April 2013, the initial presentation, the PD-L1 testing, was not performed at that time. After the diagnosis was made, a PET scan was done to confirm the findings on the CAT scan, and the patient, indeed, had stage 4 squamous cell lung cancer. Based on the histology and the stage, the patient was started on carboplatin/Abraxane. The patient received 2 cycles, and a subsequent CAT scan showed disease response on all sites. The patient felt better and had improved quality of life, as well as improved shortness of breath and cough. The patient went on to receive a total of 6 cycles of carboplatin/Abraxane, and after the sixth cycle, she had achieved stable disease when compared to the CAT scan after 2 cycles.
The patient was then just monitored and did quite well up until roughly a year later. In June/July of 2014, a surveillance scan picked up on a new left upper lobe mass that was roughly 2 cm. Given how long the patient had had stable disease, that lesion was biopsied and confirmed to be squamous cell. At that time, the patient was presented in a tumor board because she was going to be considered for local therapies. This was done because she had such a long interval of disease stability and had done quite well, and the decision rendered at the multidisciplinary tumor board was to give her local therapy to the left upper lobe lesion. She received stereotactic radiosurgery and did quite well with that modality.
The patient was then followed again and did not receive any further systemic chemotherapy up until around 9 months later, where she developed more symptoms of shortness of breath and cough. At that time, a CAT scan revealed that all sites of disease were growing in the lung, with the adrenal gland remaining fairly stable. The decision was rendered that she warranted subsequent therapy and, based on that, was offered a checkpoint inhibitor with nivolumab.
This patient presents like many squamous cell patients present: with shortness of breath and cough. And oftentimes, squamous cell presents with masses that are centrally located. In this patient, it was a little different. She presented with a mass that was more peripheral; however, she had pleural thickening as well as an adrenal metastasis. And unfortunately, this is not uncommon. Most patients, whether they have squamous cell or adenocarcinoma, 60% of them present with advanced stage disease, and this patient is no different than the patients that I see in my clinic every day.
Transcript edited for clarity.
April 2013
October 2015
June 2016
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More